Top

Published in:

01-03-2019 | Editorial

Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth

Authors: Clara E. Dismuke-Greer, Wing-Kin Syn

Published in: Digestive Diseases and Sciences | Issue 3/2019

Excerpt

Nonalcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in the USA and in other developed nations, is associated with metabolic risk factors including obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, and “non-classical” risk factors such as obstructive sleep apnea and gout [1]. In the USA, the true prevalence of NAFLD is 25–40%, depending on the modalities used to diagnosis NAFLD, and is in parallel with the rising tide of obesity and T2DM [2, 3]. As cardiovascular disease and extrahepatic cancers are the most common causes of death among those with NAFLD [4, 5], NAFLD is now considered a multi-systemic metabolic disease. …

Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol. 2006;54:229–239.PubMed

Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed

Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–133. https://doi.org/10.1002/hep.29466.CrossRefPubMed

Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–1197.CrossRefPubMed

Adams LA, Anstee QM, Tilg H, et al. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–1153.CrossRefPubMed

Younossi Z, Stepanova M, Ong JP et al. Global nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.0.

Ertle J, Dechêne A, Sowa JP, et al. Nonalcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436–2443.CrossRefPubMed

Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810–817.CrossRefPubMed

Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed

10.

Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–601.e1.CrossRefPubMed

11.

Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–31.e1.CrossRefPubMed

12.

Nguyen AL, Nguyen MH, Park H, et al. Rising inpatient encounters and economic burden for patients with nonalcoholic fatty liver disease in the USA. Dig Dis Sci. (Epub ahead of print). https://doi.org/10.1007/s10620-018-5326-7.

13.

Herzer K, Hofmann TG, Teufel A, et al. IFNalpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009;69:855–862.CrossRefPubMed

14.

Cazanave SC, Mott JL, Elmi NA, et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem. 2009;284:26591–26602.CrossRefPubMedPubMedCentral

15.

Bettermann K, Vucur M, Haybaeck J, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010;17:481–496.CrossRefPubMed

16.

Huang K-W, Leu H-B, Wang Y-J, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15:830–835.CrossRefPubMed

17.

Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.CrossRef

18.

Musso G, Gambino R, Tabibian JH, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.CrossRefPubMedPubMedCentral

19.

Lee D-H, Jacobs DR, Gross M, et al. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005;51:1185–1191.CrossRefPubMed

20.

Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564–1570.CrossRefPubMedPubMedCentral

21.

Sung K-C, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98:3637–3643.CrossRefPubMed

22.

Cartmell KB, Dismuke CE, Dooley M, et al. Effect of an evidence-based inpatient tobacco dependence treatment service on 1-year postdischarge health care costs. Med Care. 2018;56:883–889.CrossRefPubMedPubMedCentral

23.

Sayiner M, Otgonsuren M, Cable R, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51:254–260.PubMed

24.

Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–1586.CrossRefPubMed

25.

Polgreen LA, Brooks JM. Estimating incremental costs with skew: a cautionary note. Appl Health Econ Health Policy. 2012;10:319–329.CrossRefPubMedPubMedCentral

26.

Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed

Title: Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth
Authors: Clara E. Dismuke-Greer
Wing-Kin Syn
Publication date: 01-03-2019
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 3/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-018-5426-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2019

Acknowledgment of 2018 Reviewers

Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy

Delayed Bleeding After Colorectal Endoscopic Submucosal Dissection: When Is Emergency Colonoscopy Needed?

Usefulness of Thiopurine Monotherapy for Crohn’s Disease in the Era of Biologics: A Long-Term Single-Center Experience

Autoimmune Enteropathy: An Updated Review with Special Focus on Stem Cell Transplant Therapy

Concise Commentary: Caution, Not Cauterization—Management of Post-ESD Colorectal Hemorrhage

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page